Skip to content

Hydrogen-rich Water for Non-alchoholic Fatty Liver Disease

Effects of Hydrogen-rich Water on Liver Fat Accumulation, Blood Lipids and Body Fatness in Patients With Non-alchoholic Fatty Liver Disease

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03625362
Enrollment
10
Registered
2018-08-10
Start date
2018-09-01
Completion date
2018-12-31
Last updated
2019-04-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Alcoholic Fatty Liver Disease

Brief summary

This study evaluates how 4-week supplementation with hydrogen-rich water affects liver fat accumulation, blood lipid profiles and body composition in patients with non-alcoholic fatty liver disease

Detailed description

Non-alcoholic fatty liver disease (NAFLD) is a metabolic disorder characterized by liver fat deposition due to causes other than excessive alcohol consumption. NAFLD can cause many liver dysfunction-related symptoms and signs, with the disease may progress to non-alcoholic steatohepatitis, a condition marked by liver inflammation, fibrosis and irreversible damage. NAFLD is usually accompanied by insulin resistance and obesity, with up to 30% of population in industrialized countries have NAFLD. While NAFLD is rapidly becoming the most common liver disease worldwide, its treatment remains elusive, and directed toward correction of the risk factors. Since metabolic impairment plays a major role in NAFLD pathogenesis, any agent that advance lipid and glucose metabolism could be appropriate to tackle this complex condition. Molecular hydrogen (H2) has recently emerged as a novel pro-metabolic agent that might positively affect liver health. Supplemental hydrogen improves blood lipid profiles and insulin resistance in overweight women, patients with type 2 diabetes, and in subjects with potential metabolic syndrome. In addition, drinking hydrogen-rich water reduces hepatic oxidative stress and alleviated fatty liver damage in rodents. However, no human studies so far evaluated its effectiveness to alter liver steatosis in patients with NAFLD. In this pilot trial, we analyze the effects of 4-week hydrogen-rich water intake on liver fat deposition, body composition and lab chemistry profiles in overweight patients suffering from NAFLD.

Interventions

DIETARY_SUPPLEMENTHydrogen

Hydrogen-rich water

DIETARY_SUPPLEMENTPlacebo

Tap water

Sponsors

University of Novi Sad, Faculty of Sport and Physical Education
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 years * Body mass index \> 25 kg/m2 * Free of major diseases besides NAFLD * Must be able to give written informed consent

Exclusion criteria

* Use of any dietary supplements within 4 weeks before study commences * Abnormal values for lab clinical chemistry (\> 2 SD)

Design outcomes

Primary

MeasureTime frameDescription
Liver fat contentChange from baseline liver triglycerides at 4 weeksMRS spectra for liver triglycerides

Secondary

MeasureTime frameDescription
Total cholesterolChange from baseline total cholesterol at 4 weeksLevel of total cholesterol in the blood
Total body fatnessChange from baseline fat percentage at 4 weeksFat percentage evaluated by BIA

Countries

Serbia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 3, 2026